Rafael Holdings, Inc. (RFL) stock: key figures, P/E, revenue and dividend

Health Care · United States · ISIN US75062E1064

Price
1.12 USD
Market cap
32.95 m USD
P/E (2026)
–
P/S (2026)
37.70
Dividend yield
0.00 %
Net margin
-3,390.73 %
Return on equity (ROE)
-44.69 %
Return on assets (ROA)
-35.68 %

Rafael Holdings, Inc. financials

Fiscal year20252026
Revenue917,000.00 USD874,000.00 USD
Operating income-29.16 m USD-33.41 m USD
EBIT-32.54 m USD-27.63 m USD
Net income-30.52 m USD-29.64 m USD
Diluted EPS – continuing operations-1.04 USD-0.58 USD

Full history since 2015, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

About Rafael Holdings, Inc.

Rafael Holdings, Inc. primarily engages in holding interests in clinical and early-stage pharmaceutical companies, and medical devices in the United States and Israel. It operates in three segments, Healthcare, Infusion Technology, and Real Estate. The company engages in the development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells. Its lead drug candidate is Trappsol Cyclo, which is in phase 3 clinical trial being evaluated for the potential treatment of Niemann-Pick Disease Type C1 ("NPC1"), a rare, fatal and progressive genetic disorder; and CPI-613 (devimistat), a stable analog of normally transient, acylated catalytic intermediates of lipoate, which is in phase II of clinical trial. The company is also involved in developing Promitil, a molecule designed for the targeted delivery of mitomycin-C in a proprietary prodrug form, completed Phase 1A and 1B clinical studies targeting patients with advanced cancers. In addition, it engages in the development of surgical and procedural devices, including orthopedic arthroscopy instrument for Carpal Tunnel syndrome. Rafael Holdings, Inc. was incorporated in 2017 and is headquartered in Newark, New Jersey.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 29.10.2026. Details in the risk notice.